Skip to main content


Health

Novartis says that it now seeks approval for serelaxin. Researchers say that in a study of 1,161 patients, the drug cut deaths from any cause at six months by 37 percent and led to a marked reduction in worsening of heart failure during hospitalization.
676 of 1663




Newsletter Sign Up

Saint of the Day

March 4 Saint of the Day

St. Casimir
March 4: Casimir grew up in a world where his life was not his own. As a ... Read More